首頁 > 市場調查報告書 > 製藥

癌症呼吸器

市場調查報告書

商品編碼

1819081

肺癌抗體藥物複合體的全球市場:市場機會，專利，價格，臨床試驗相關洞察(2030年)

Global Lung Cancer Antibody Drug Conjugates Market Opportunity, Patent, Price & Clinical Trials Insight 2030

出版日期: 2025年09月01日 | 出版商:

KuicK Research | 英文 250 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球肺癌抗體-藥物偶聯物市場：市場機會、專利、定價和臨床試驗洞察（2030 年）報告結果和亮點

研究方法
全球肺癌抗體-藥物偶聯物市場機會：20 億美元
全球及地區趨勢
已獲得商業批准的肺癌抗體-藥物偶聯物（按品牌名稱、公司和適應症劃分）
已核准的肺癌抗體-藥物偶聯物的專利、劑量和價格分析
臨床試驗中肺癌抗體-藥物偶聯物的洞察：120 種藥物偶聯物
肺癌抗體-藥物偶聯物臨床試驗洞察：按公司、國家、適應症和階段
癌症抗體-藥物偶聯物開發平台（按公司）

肺癌治療對抗體-藥物偶聯物的需求及本報告的意義

肺癌是全球最具挑戰性的癌症之一，發病率和死亡率都很高。手術、化療和放療等傳統治療方法已被廣泛應用，但長期療效往往不理想，尤其是在晚期和轉移性病例中。因此，對更特異性和更有效治療方法的需求推動了新型療法的發展，例如抗體-藥物偶聯物 (ADC)，它將抗體的特異性與化療的強效抗癌活性相結合。抗體藥物偶聯物旨在優先攻擊癌細胞，從而最大程度地減少對正常組織的損害並降低全身毒性，與傳統療法相比具有顯著優勢。隨著肺癌的分子和遺傳複雜性不斷演變，抗體偶聯藥物 (ADC) 被認為是提高小細胞肺癌 (SCLC) 和非小細胞肺癌 (NSCLC) 患者存活率的關鍵。

本報告對肺癌抗體偶聯藥物市場進行了深入分析，為利益相關者提供了有關當前臨床試驗、創新技術以及定義該市場的關鍵公司的重要資訊。報告揭示了關鍵的臨床試驗結果，監測了有前景的藥物的進展，並探索了推動該市場發展的合作機會。

本報告包含的肺癌抗體偶聯藥物臨床試驗洞察

本報告的一大亮點是全面討論了肺癌抗體偶聯藥物的當前和已完成的臨床試驗。報告概述了臨床試驗階段、地區和贊助公司，並深入分析了抗體偶聯藥物的臨床定位。例如，針對 B7-H3 的抗體藥物偶聯物 ifinatamab deruxtecan (i-DXd) 目前正在進行廣泛期小細胞肺癌 (SCLC) 的臨床試驗。本報告詳細討論了研究目標，例如評估該藥物對總存活期和緩解率的影響，這些目標可用於指導臨床決策。

此外，我們也展示了這些試驗的地理分佈，展現了肺癌抗體-藥物偶聯物開發的全球性。我們也探討了正在研究的適應症，並重點介紹了各種抗體-藥物偶聯物對哪些肺癌亞型有效。本報告不僅提供了臨床階段數據，還提供了關鍵的試驗結果，準確概述了抗體-藥物偶聯物在肺癌治療中的開發情況。

技術平台、合作與協議

抗體-藥物偶聯物的成功在很大程度上取決於用於開發和提供此類療法的技術平台。本分析檢視了頂級製藥公司成功開發肺癌抗體-藥物偶聯物所使用的尖端平台。例如，第一三共的DXd平台以其可裂解連接子、拓樸異構酶I抑制劑有效載荷和高活性細胞毒藥物的整合而聞名。他為Enhertu和Datroway的研發做出了貢獻，這些藥物已被證明對HER2和EGFR突變的非小細胞肺癌（NSCLC）有效。

本報告也檢視了大型製藥公司之間日益增多的合作，例如默克公司與第一三共公司合作開發針對免疫檢查點靶點（例如SCLC中的B7-H3）的抗體-藥物偶聯物。此類合作對於將抗體-藥物偶聯物推向臨床並使其更接近批准至關重要。透過研究這些合作和技術平台，本報告清楚地描繪了推進抗體-藥物偶聯物開發的先進策略。

活躍於肺癌治療研發的主要公司

本報告全面分析了開發基於抗體-藥物偶聯物的肺癌療法的主要製藥和生物技術公司。抗體-藥物偶聯物開發的主要公司包括阿斯特捷利康、第一三共、輝瑞和百時美施貴寶。領先的公司正在開發針對不同腫瘤抗原（例如 HER2、TROP-2 和 B7-H3）的有前景的抗體-藥物偶聯物產品線，這些抗原在肺癌治療中發揮著重要作用。

本報告重點介紹這些公司正在進行的研究活動，包括提高抗體-藥物偶聯物的強度和特異性。透過分析這些行業領導者，本報告揭示了圍繞抗體-藥物偶聯物開發的競爭動態，並深入了解哪些公司正在引領肺癌治療的進步。

一份關於抗體-藥物偶聯物在肺癌治療中未來發展方向的報告。

本報告闡明了抗體-藥物偶聯物在肺癌治療中的未來前景，以及未來的趨勢和技術將如何定義市場。抗體-藥物偶聯物越來越多地與其他療法（例如免疫檢查點抑制劑和抗血管生成藥物）聯合使用。這種方法的目標是最大限度地提高抗體-藥物偶聯物的治療指數，並對抗患者可能出現的抗藥性機制。

本報告也預測了更個人化的治療方法的趨勢，其中抗體-藥物偶聯物旨在針對個別患者中普遍存在的特定基因突變或腫瘤抗原。這是評估patritumab deruxtecan（一種針對HER3的抗體藥物偶聯物）的臨床試驗的模式，該藥物專門針對具有特定EGFR突變的NSCLC患者。這些趨勢表明，抗體-藥物偶聯物不僅可以用作單一療法，還可以成為更全面、多組分治療方案的一部分。

透過回顧趨勢和方向，本報告展示了抗體-藥物偶聯物在肺癌治療中的未來前景，並為這一快速發展的治療領域的相關利益相關者提供了有用的建議。

Research Methodology
Global Lung Cancer Antibody Drug Conjugates Market Opportunity: > US$ 2 Billion
Global & Regional Trends Insight
Commercially Approved Lung Cancer Antibody Drug Conjugates By Brand Name, Company & Indication
Approved Lung Cancer Antibody Drug Conjugates Patent, Dosage & Price Analysis
Insight On Lung Cancer Antibody Drug Conjugates In Clinical Trials: > 120 Drug Conjugates
Lung Cancer Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication & Phase
Cancer Antibody Drug Conjugates Development Platforms By Company

Need For Antibody Drug Conjugates Lung Cancer Treatment & Why This Report

Lung cancer's high incidence and mortality rates make it one of the most challenging cancers to manage globally. While traditional therapies like surgery, chemotherapy, and radiotherapy have been employed, they often fail to provide long-term results, especially in the case of advanced or metastatic disease. As a result, the demand for more specific, effective therapies has prompted the creation of novel therapies, such as antibody drug conjugates (ADCs), which provide a high potential alternative by fusing the specificity of antibodies with the potent anti-cancer activity of chemotherapy. Antibody drug conjugates are designed to preferentially attack cancer cells, thus reducing harm to normal tissue and lowering systemic toxicity, giving them a huge benefit over traditional treatments. As lung cancer's molecular and genetic intricacies continuing to evolve, ADCs are being viewed as essential to enhancing survival for both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) patients.

This report provides an in-depth analysis of the lung cancer antibody drug conjugates market, giving its stakeholders important information on current clinical trials, innovative technology, and leading players defining this market. It brings to light significant trial outcomes, monitors the advancement of promising drugs, and examines the collaborations that are driving this space.

Lung Cancer Antibody Drug Conjugates Clinical Trials Insight Included In the Report

One of the prominent aspects of the report is its comprehensive discussion of current and finished clinical trials for antibody drug conjugates in lung cancer. The report outlines clinical trial phases, geography, and sponsoring companies, providing a detailed insight into where antibody drug conjugates are in their clinical stage. For example, Ifinatamab Deruxtecan (I-DXd), an antibody drug conjugate that targets B7-H3, is in clinical trials for extensive stage SCLC. The report discusses in detail the purpose of the trial, such as assessing the drug's effect on overall survival and response rates, which can be used for decision making in clinical practice.

Additionally, the report indicates the geographical distribution of these trials, indicating the global nature of antibody drug conjugate development for lung cancer. It also explores the indications under investigation, highlighting which lung cancer subtypes are being addressed by various antibody drug conjugates. The information in the report not only gives trial phase data but also indicates key trial results, giving an accurate snapshot of antibody drug conjugate development in the treatment of lung cancer.

Technology Platforms, Collaborations & Agreements

The success of antibody drug conjugates is largely dependent on the technology platforms utilized to develop and provide such therapies. This analysis gets close to the front-running platforms used by top pharma companies to develop successful antibody drug conjugates against lung cancer. For instance, Daiichi Sankyo's DXd platform is noted for its integration of a cleavable linker, a topoisomerase I inhibitor payload, and a highly active cytotoxic drug. It was responsible for creating Enhertu and Datroway, which have proved effective in HER2- and EGFR-mutated NSCLC.

Moreover, the report investigates increasing partnerships among big pharma companies, like the collaboration between Merck and Daiichi Sankyo for antibody drug conjugate development against immune checkpoint targets like B7-H3 in SCLC. These partnerships are imperative in driving antibody drug conjugates through the clinic and closer to approval. By reviewing these partnerships and tech platforms, the report depicts the advanced strategies driving antibody drug conjugate development clearly.

Major Companies Active In R&D For Lung Cancer Treatment

The report provides a comprehensive analysis of leading pharmaceutical and biotech companies developing antibody drug conjugate based therapy for lung cancer. AstraZeneca, Daiichi Sankyo, Pfizer, and Bristol Myers Squibb are identified as leading companies in developing antibody drug conjugates. The leading companies are developing a pipeline of promising antibody drug conjugates that target different tumor antigens such as HER2, TROP-2, and B7-H3, all of which play an important role in the treatment of lung cancer.

The report highlights these firms for their continued research activities, such as improving the strength and specificity of their antibody drug conjugates. Through profiling these industry leaders, the report sheds light on the competitive dynamics surrounding antibody drug conjugate development and providing insight as to who among these firms are leading the way in lung cancer treatment advancement.

Report Suggesting Future Direction Of Antibody Drug Conjugates Lung Cancer Treatment

Looking forward, the report provides a glimpse into what the future holds for antibody drug conjugates in lung cancer therapy, and how upcoming trends and technologies may define the market. An important area covered is the growing emphasis on combination therapies, whereby antibody drug conjugates are being combined with other therapeutic modalities like immune checkpoint inhibitors and angiogenesis inhibitors. The purpose of this approach is to maximize the therapeutic index of antibody drug conjugates and counter mechanisms of resistance that could develop in patients.

The report also foresees a trend towards more personalized treatment approaches, where antibody drug conjugates are engineered to attack particular genetic mutations or tumor antigens prevalent in individual patients. This is the pattern with clinical trials evaluating Patritumab Deruxtecan, an antibody drug conjugate against HER3, prepared specifically for NSCLC patients harboring particular EGFR mutations. These trends imply that antibody drug conjugates will not only be employed as monotherapies but may instead become part of more comprehensive, multi component treatment protocols.

Through the examination of trends and directions, the report presents a forward looking view of antibody drug conjugates in lung cancer therapy, providing useful advice for interested stakeholders in the field of this fast moving therapeutic area.

1. Introduction To Lung Cancer Antibody Drug Conjugates

1.1 Overview
1.2 Mechanism Of Antibody Drug Conjugates

2. Antibody Drug Conjugates As Lung Cancer Targeted Therapy

2.1 Applications Of Antibody Drug Conjugates In Lung Cancer
2.2 Advantages Of Antibody Drug Conjugates
2.3 Comparison Of Antibody Drug Conjugates With Traditional Therapies
2.4 Lung Cancer Antibody Drug Conjugates Combination Therapies

3. Generations Of Lung Cancer Antibody Drug Conjugates

3.1 Antibody Drug Conjugates - Evolution
3.2 Next Generation Antibody Drug Conjugates Prospects

4. Commercially Approved Lung Cancer Antibody Drug Conjugates By Brand Name, Company & Indication

5. Global Lung Cancer Antibody Drug Conjugates Market Outlook

5.1 Current Market Scenario
5.2 Global Lung Cancer Antibody Drug Conjugates Market Trends & Development
5.3 Future Growth Avenues

6. Global Lung Cancer Antibody Drug Conjugates Research & Market Trends by Region

6.1 US
6.2 China
6.3 Europe
6.4 Japan
6.5 South Korea

7. Approved Lung Cancer Antibody Drug Conjugates - Patent, Dosage & Price Analysis

7.1 Enhertu
- 7.1.1 Overview, Availability & Patent Insight
- 7.1.2 Pricing & Dosage Insight
7.2 Sacituzumab Tirumotecan
- 7.2.1 Overview, Availability & Patent Insight
7.3 Datroway
- 7.3.1 Overview & Availability Insight
- 7.3.2 Dosage & Price Analysis
7.4 Emrelis
- 7.4.1 Overview & Availability Insights
- 7.4.2 Pricing & Dosing Insight
7.5 Trastuzumab Rezetecan
- 7.5.1 Overview & Availability Insight

8. Global Lung Cancer Antibody Drug Conjugates Clinical Trials Overview

8.1 By Phase
8.2 By Indication
8.3 By Company
8.4 By Fast Track & Orphan Status
8.5 By Country

9. Global Lung Cancer Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication & Phase

9.1 Research
9.2 Preclinical
9.3 Phase I
9.4 Phase I/II
9.5 Phase II
9.6 Phase II/III
9.7 Phase III
9.8 Registration

10. Marketed Cancer Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication & Phase

11. Cancer Antibody Drug Conjugates Development Platforms By Company

12. Global lung Cancer Antibody Drug Conjugates Market Dynamics

12.1 Key Market Growth Drivers
12.2 Challenges For Market Growth

13. Competitive Landscape

13.1 ADC Therapeutics
13.2 AstraZeneca
13.3 Biocytogen
13.4 Biokin
13.5 Bristol Myers Squibb
13.6 Daiichi Sankyo
13.7 Duality Biologics
13.8 Gilead
13.9 Immunogen
13.10 Innovent Biologics
13.11 Kelun Biotech
13.12 LigaChem Biosciences
13.13 Merck
13.14 Pfizer
13.15 Roche

簡介目錄圖表

List of Figures

Figure 1-1: Antibody Drug Conjugates - General Working Mechanism
Figure 2-1: Advantages of Antibody Drug Conjugates
Figure 2-2: Lung Cancer - Antibody Drug Conjugate Combinations In Studies
Figure 3-1: Cancer Antibody Drug Conjugates - Opportunities For Next-Generation Development
Figure 5-1: Global - Lung Cancer Antibody Drug Conjugates Market (US$ Million), 2023-2025
Figure 5-2: IDeate-Lung02 Phase 3 (NCT06203210) Study - Initiation & Completion Year
Figure 5-3: SGNB6A-001 Phase 1 (NCT04389632) Study - Initiation & Completion Year
Figure 5-4: SGNB6A-002 Phase 3 (NCT06012435) Study - Initiation & Completion Year
Figure 5-5: MK-2870-004 Phase 3 (NCT06074588) Study - Initiation & Completion Year
Figure 5-6: SHR-4849-101 Phase 1 (NCT06443489) Study - Initiation & Completion Year
Figure 5-7: Global - Lung Cancer Antibody Drug Conjugate Market Forecast (US$ Million), 2026 - 2030
Figure 7-1: Enhertu - Cost Of Supply In US & Europe (US$), September'2025
Figure 7-2: Datroway - Cost Of 100 mg Supply In US & Europe (US$), September'2025
Figure 7-3: Emrelis - Cost Per Supply (US$), September'2025
Figure 8-1: Global - Lung Cancer Antibody Drug Conjugate In Clinical Trials By Phase, 2025 Till 2030
Figure 8-2: Global- Cancer Antibody Drug Conjugate In Clinical Trials By Indication, 2025 Till 2030
Figure 8-3: Global - Cancer Antibody Drug Conjugate In Clinical Trials By Company, 2025 Till 2030
Figure 8-4: Global - Cancer Antibody Drug Conjugate In Clinical Trials By Fast Track & Orphan Status, 2025 Till 2030
Figure 8-5: Global - Cancer Antibody Drug Conjugate In Clinical Pipeline By Country, 2025 Till 2030
Figure 11-1: Proprietary ADC Technology - Seagen
Figure 11-2: ALE.P02 & ALE.P03 - Alentis Therapeutics
Figure 11-3: TRAAC - Tallac Therapeutics
Figure 11-4: ATAC - Heidelberg Pharma
Figure 11-5: Tub-tag(R) & P5 - Tubulis

List of Tables

Table 2-1: Lung Cancer - Antibody Drug Conjugates vs. Traditional Therapies
Table 2-2: Lung Cancer - Ongoing Antibody Drug Conjugate Combination Clinical Trials
Table 3-1: Lung Cancer - Approved Second Generation Antibody Drug Conjugates
Table 3-2: Lung Cancer - Approved Third Generation Antibody Drug Conjugates
Table 3-3: Lung Cancer - Approved Fourth Generation Antibody Drug Conjugates
Table 3-4: Lung Cancer - Summary Of Antibody-Drug Conjugate Generations
Table 4-1: Lung Cancer - Approved Antibody Drug Conjugates, September'2025
Table 6-1: US - Approved Lung Cancer Antibody Drug Conjugates, September'2025
Table 6-2: China - Approved Lung Cancer Antibody Drug Conjugates, September'2025
Table 6-3: EU - Approved Cancer Antibody Drug Conjugates, September'2025
Table 6-4: Japan - Approved Cancer Antibody Drug Conjugates, September'2025
Table 7-1: Datroway - Premedication & Concomitant Medications
Table 7-2: Datroway - Recommended Dosage Reductions For Adverse Reactions
Table 7-3: Emrelis: Recommended Dose Reductions